Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2017-2023
Historical Year
2024-2032
Forecast Year
Global Viral Vector Manufacturing Market Outlook
The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, driven by increased funding for gene therapy development. The market is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032, with the values likely to rise from USD 3.2 billion in 2024 to USD 13.5 billion by 2032.
Global Viral Vector Manufacturing Market Overview
Viral vectors are efficient gene transfer vehicles that are commonly used by molecular biologists to manipulate a specific cell type or tissue for certain therapeutic purposes. The viral vector manufacturing market is witnessing a steady rise due to increased research and development activities aimed at the early diagnosis and effective treatment of several medical conditions. In April 2023, a study published in the New England Journal of Medicine revealed the genetic cause of severe developmental diseases in about 5,500 patients. With a rise in the prevalence of genetic disorders along with technical advancements in diagnostic methods, the viral vector manufacturing market demand is expected to fuel in the coming years.
Several leading players in the market are actively investing in the capacity expansion for viral vector manufacturing activities. In June 2023, SK Inc.'s subsidiary SK Pharmteco, a global contract development and manufacturing organization headquartered in California, announced the establishment of its second facility for cell and gene therapies (CGT) manufacturing in Europe spanning 5000 square meters. The new facility specializes in the bioproduction of lentiviral vectors (LV) and adeno-associated virus (AAV). With the help of its commercial viral vector manufacturing subsidiary for CGTs, the company is expanding its presence in the market. The surge in investments to scale up viral vector production are anticipated to propel the viral vector manufacturing market growth in the forecast period.
The market is also driven by the rise in government initiatives and programs to fuel viral vector manufacture and development. The rising healthcare expenditure to improve patient outcomes is another factor, poised to aid expansion of the market size.
Global Viral Vector Manufacturing Market Trends
| Key Trends | Description |
| Increased Investment in Gene Therapy | With rising interest in gene therapy for treating genetic disorders, investment in viral vector manufacturing is growing. This includes funding for research, development, and scaling production capabilities. |
| Advances in Production Technologies | Technological improvements in bioreactors and downstream processing are enhancing yield and purity. These advances reduce costs for viral vector-based therapies. |
| Regulatory Evolutions | Regulatory health agencies are adapting frameworks to ensure the safety and efficacy of viral vector-based treatments. In addition, rapid approval processes for gene therapies and vaccines are positively impacting market dynamics. |
| Expansion into Emerging Markets | Companies are expanding their geographic presence to tap into emerging markets, where there's a growing demand for advanced therapeutics. This includes establishing manufacturing facilities and partnerships in these regions. |
Global Viral Vector Manufacturing Market Segmentation
Market Breakup by Vector Type
- Retroviral Vectors
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral (AAV) Vectors
- Herpes Simplex Viral (HSV) Vectors
- Vaccinia Viral Vectors
- Others
The market is segmented by vector type into retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes simplex viral (HSV) vectors, vaccinia viral vectors, and others. This segmentation offers an overview of the various types of vectors used in gene therapy and research.
Market Breakup by Indication Type
- Cancer
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
By indication type, the market is segmented into cancer, genetic disorders, infectious diseases, cardiovascular diseases, neurological disorders, and others. This market segment elucidates the applications of viral vector manufacturing across various medical conditions. Cancer stands as a prominent indication, with viral vectors utilized in gene therapy approaches targeting tumor cells. This segmentation reflects the potential of viral technology for effective therapeutic intervention, which is poised to boost the viral vector manufacturing market share in the forecast period.
Market Breakup by Application
- Gene Therapy
- Vaccinology
- Drug Discovery and Development
- Others
Applications of the market include gene therapy, vaccinology, drug discovery and development, and others. This segmentation highlights the diverse uses of viral vectors across different medical and scientific fields.
Market Breakup by Production System
- Baculovirus Expression System
- Mammalian Cell Expression System
- Insect Cell Expression System
- Others
The market breakup by production system includes the baculovirus expression system, mammalian cell expression system, insect cell expression system, and others. Each production system offers a set of unique advantages. These systems are selected based on factors such as scalability, efficiency, and downstream processing requirements in viral vector manufacturing.
Market Breakup by Production Scale
- Large-Scale Production
- Mid-Scale Production
- Small-Scale Production
The viral vector manufacturing market report also includes breakup by production scale as well. It comprises large-scale production, mid-scale production, and small-scale production. The various production capacities are aligned to specific market demands and applications to ensure efficient and cost-effective viral vector manufacturing.
Market Breakup by End User
- Biopharmaceutical Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Research Institutes
- Others
End users of the market are biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutes, and others. This segmentation reflects the range of users that contribute to the market of viral vector manufacturing.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market breakup by region covers several major markets including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is dominating the market share which can be attributed to the presence of key pharmaceutical and biotechnology companies, research facilities, and a robust healthcare infrastructure in the region.
Global Viral Vector Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Catalent, Inc.
- Merck KGaA (MilliporeSigma)
- FUJIFILM Diosynth Biotechnologies
- WuXi AppTec Co., Ltd.
- Cobra Biologics (Acquired by Pall Corporation)
- VGXI, Inc.
- Sartorius AG
- Kaneka Eurogentec S.A.
- Vigene Biosciences, Inc.
- Oxford Biomedica plc
- Cell and Gene Therapy Catapult
- Rentschler Biopharma SE
- 4D Molecular Therapeutics
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Vector Type |
|
| Breakup by Indication Type |
|
| Breakup by Application |
|
| Breakup by Production System |
|
| Breakup by Production Scale |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Global Viral Vector Manufacturing Market Report
- How is the market landscape expected to evolve in the coming years?
- What are the major trends influencing the market?
- What are the significant drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to witness rapid growth during the forecast period?
- Which vector types are expected to dominate the respective market segment?
- Which indication type will result in the expansion of viral vector manufacturing market size?
- Which applications are expected to impact the growth of the market significantly?
- Which production system will dominate the market in the forecast period?
- What are the key research initiatives expected to boost the market value during the forecast period?
- Which type of production scale has high demand in the market?
- What major companies are involved in the supplier landscape of the market?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market attained a value of about USD 2.6 billion in 2023 driven by driven by increased funding for gene therapy development across the globe.
The market is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032, likely to reach a market value of USD 13.5 billion by 2032.
The rising prevalence of genetic disorders along with the growing impetus on the development of novel therapeutics are fuelling the demand for the market.
One of the significant trends in the market is the rising investment in capacity expansion for viral vector manufacturing activities. In June 2023, SK Inc.'s subsidiary SK Pharmteco, announced the establishment of its second facility for cell and gene therapies (CGT) manufacturing in Europe spanning 5000 square meters.
Based on the vector type, the market is segmented into retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes simplex viral (HSV) vectors, vaccinia viral vectors, and others.
By indication type, the market is segmented into cancer, genetic disorders, infectious diseases, cardiovascular diseases, neurological disorders, and others.
Various production systems include the baculovirus expression system, mammalian cell expression system, insect cell expression system, and others.
Based on the production scale, the market is segmented into large-scale production, mid-scale production, and small-scale production.
End users of the market are biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutes, and others.
Common application areas include gene therapy, vaccinology, drug discovery and development, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Lonza Group AG, Thermo Fisher Scientific Inc., Catalent, Inc., Merck KGaA (MilliporeSigma), FUJIFILM Diosynth Biotechnologies, WuXi AppTec Co., Ltd., Cobra Biologics (Acquired by Pall Corporation), VGXI, Inc., Sartorius AG, Kaneka Eurogentec S.A., Vigene Biosciences, Inc., Oxford Biomedica plc, Cell and Gene Therapy Catapult, Rentschler Biopharma SE, and 4D Molecular Therapeutics.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124